Brooks Laboratories Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Brooks Laboratories Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 37% in 3 years; of every extra ₹100 of sales, ₹199 became extra profit. Higher than almost all Healthcare companies in India.
- Tangible Net Worth Ratio: Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 98% of Healthcare companies in India.
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 98% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
0.4×Over the last 3 years its own operating cash paid for 44% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Lower than 84% of Healthcare companies in India.
Cash Locked Ratio
₹17For every ₹100 of sales, ₹17 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹1 from others' credit three years earlier.
Less money tied up than 64% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹199Sales grew 37% in 3 years; of every extra ₹100 of sales, ₹199 became extra profit.
Higher than almost all Healthcare companies in India.
Asset Productivity Ratio
+37% / +35%In 3 years sales changed by +37% while total assets changed by +35%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
1.5×Debt due within a year is covered 1.5 times by its yearly operating cash.
Higher than 53% of Healthcare companies in India.
Cash Cushion Ratio
−1%Debt, after subtracting cash, equals 1% of its market value (net debt).
Higher than 50% of Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 98% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 98% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Brooks Laboratories Limited owes ₹0.17 for every ₹1 it owns. Brooks Laboratories Limited returned to profit in the year to Mar 2026, after a loss the year before.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
13.6Investors pay ₹13.6 for every ₹1 of Brooks Laboratories Limited's yearly profit, lower than 91% of Healthcare companies in India.
P/B ratio
1.47The share price is 1.47 times Brooks Laboratories Limited's book value per share, lower than 93% of Healthcare companies in India.
Market cap
₹180 CrThe total market value of all of Brooks Laboratories Limited's shares at today's price (share price × number of shares), smaller than 91% of Healthcare companies in India. PosiCap size class: Micro Cap.
Net worth (book value)
₹123 CrWhat Brooks Laboratories Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹41.64Net worth divided by the number of shares. The share price of ₹61.09 is 1.5 times this, which is the P/B above.
Return on equity (ROE)
10.8%Brooks Laboratories Limited earned 10.8% on its shareholders' money over the last year, lower than 62% of Healthcare companies in India.
Owes vs Owns
0.17×Brooks Laboratories Limited owes ₹0.17 for every ₹1 it owns (low), lower than 86% of Healthcare companies in India.
Dividend yield
NoneBrooks Laboratories Limited does not currently pay a dividend.
Revenue growth
+4%Revenue rose 4% in the year to Mar 2026, and grew 11% a year on average over 3 years.
Profit growth
Back to profitBrooks Laboratories Limited returned to profit in the year to Mar 2026, after a loss the year before.
Profit margin
28.8%Brooks Laboratories Limited keeps ₹29 of every ₹100 of revenue as net profit.
Cash quality
0.4×Cash from Brooks Laboratories Limited's business was 0.4× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
7.6×Brooks Laboratories Limited's operating profit covered its interest costs 7.6 times in the year to Mar 2026.
Cash vs debt
Net debtBrooks Laboratories Limited had ₹2 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Brooks Laboratories Limited's P/E ratio?
Investors pay ₹13.6 for every ₹1 of Brooks Laboratories Limited's yearly profit, lower than 91% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Brooks Laboratories Limited: ₹180 Cr ÷ ₹123 Cr (31 Mar 2026) = 1.5.
What is Brooks Laboratories Limited's return on equity?
Brooks Laboratories Limited earned 10.8% on its shareholders' money over the last year, lower than 62% of Healthcare companies in India.
How much does Brooks Laboratories Limited owe compared with what it owns?
Brooks Laboratories Limited owes ₹0.17 for every ₹1 it owns (low), lower than 86% of Healthcare companies in India.
Does Brooks Laboratories Limited pay a dividend?
No. Brooks Laboratories Limited does not currently pay a dividend.
Is Brooks Laboratories Limited's revenue growing?
Revenue rose 4% in the year to Mar 2026, and grew 11% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.